Evaluation of Hepatocyte Growth Factor in Iraqi Patients with Acute Myeloid Leukemia: Its Correlation with Clinical Parameters and Response to Induction Therapy

its correlation with clinical parameters and response to induction therapy

  • Israa M. Al-Bayaa Department of Pathology, College of Medicine, University of Kerbala, Iraq
  • Haithem Ahmed Al-Rubaie Department of Pathology, College of Medicine, University of Baghdad, Iraq
  • Haider Hasan Al-Shammari Department of Pathology, College of Medicine, University of Baghdad, Iraq
Keywords: Acute myeloid leukemia, Hepatocyte growth factor, Remission induction


BACKGROUND: Hepatocyte growth factor (HGF) is a proangiogenic factor that exerts different effects over stem cell survival growth, apoptosis, and adhesion. Its impact on leukemogenesis has been established by many studies.

AIM: This study aimed to determine the effect of plasma HGF activity on acute myeloid leukemia (AML) patients at presentation and after remission.

PATIENTS AND METHODS: This was a cross-sectional prospective study of 30 newly-diagnosed, adult, and AML patients. All patients received the 7+3 treatment protocol. Patients’ clinical data were taken at presentation, and patients were followed up for 6 months to evaluate the clinical status. Plasma HGF levels were estimated by ELISA based methods in the patients at two intervals first at diagnosis and the 2nd time after remission of disease. Plasma HGF levels were only measured once in twenty healthy control individuals.

RESULTS: A statistically significant lowering in the median levels of HGF after remission induction therapy has been found when compared with those before treatment (p = 0.006) and in the group of patients who achieved complete remission in comparison with those before treatment (p = 0.005). Furthermore, a significant reduction was also demonstrated after treatment in patients presenting with extramedullary involvement (p = 0.003) and in the alive group (p = 0.001).

CONCLUSION: Plasma HGF estimation can be a useful parameter in predicting treatment outcomes in patients with AML, and it can add potentially useful information to risk stratification parameters.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Saultz JN, Garzon R. Acute myeloid leukemia: A concise review. J Clin Med. 2016;5(3):e33. PMid:26959069

Obeyed HH, Ibrahim RH, Ali KM, Abdo-Alkareem, Hasan AH, Nasser LM, et al. Annual Report Iraqi Cancer Registry 2016. Baghdad: Iraqi Cancer Board; 2018. Available from: https://moh. gov.iq/upload/upfile/ar/882.pdf

Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70-87. https://doi.org/10.1016/j. blre.2019.04.005 PMid:31101526

Burnett AK, Grimwade D. Acute myeloid leukaemia. In: Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB, editorss. Postgraduate Haematology. 7th ed. Chichester, UK: Wiley Blackwell; 2016. p. 352-69. https://doi.org/10.1002/9781118853771.ch20

Ossenkoppele G, Montesinos P. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. Crit Rev Oncol Hematol. 2019;138:6-13. PMid:31092386

De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: A comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441. https://doi.org/10.1038/bcj.2016.50 PMid:27367478

Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-52. PMid:26376137

Haouas H. Angiogenesis and acute myeloid leukemia. Hematology 2014;19(6):311-23. PMid:24192539

Haouas H. Angiogenesis in hematological malignancy-evaluated by dynamic contrast-enhanced MRI. J Cancer Res Pract. 2016;3(4):97-103.

Reikvam H, Hatfield KJ, Fredly H, Nepstad I, Mosevoll KA, Bruserud Ø. The angioregulatory cytokine network in human acute myeloid leukemia from leukemogenesis via remission induction to stem cell transplantation. Eur Cytokine Netw. 2012;23(4):140-53. https://doi.org/10.1684/ecn.2012.0322 PMid:23328436

Roversi FM, Cury NM, Lopes MR, Ferro KP, Machado- Neto JA, Alvarez MC, et al. Up-regulation of SPINT2/HAI-2 by azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion. J Cell Mol Med. 2019;23(2):1562-71. https://doi.org/10.1111/jcmm.14066 PMid:30484958

Guo JR, Li W, Wu Y, Wu LQ, Li X, Guo YF, et al. Hepatocyte growth factor promotes proliferation, invasion, and metastasis of myeloid leukemia cells through PI3K-AKT and MAPK/ERK signaling pathway. Am J Transl Res. 2016;8(9):3630-44. PMid:27725846

Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol. 1999;29(3):209- 48. https://doi.org/10.1016/s1040-8428(98)00019-5 PMid:10226727

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47. https://doi.org/10.1182/ blood-2016-08-733196 PMid:27895058

Quantikine® ELISA Human HGF Immunoassay Kit (Catalog Number DHG00), R&D Systems, Inc., 614 McKinley Place NE, Minneapolis, MN 55413, USA. Available from: https://www. rndsystems.com/products/human-hgf-quantikine-elisa-kit_ dhg00#product-datasheets. [Last accessed on 2017 Mar 23].

Padró T, Ruiz S, Bieker R, Bürger H, Steins M, Kienast J, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95(8):2637-44. https://doi. org/10.1182/blood.v95.8.2637 PMid:10753845

Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93(9):3064-73. https://doi.org/10.1182/blood.v93.9.3064 PMid:10216103

Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E, Folkman J. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150(3):815-21. PMid:9060819

Ahmed AE, El-Baser KA, Zytoun SS, Alsenbesy MA, Elsaid AE. Estimation of plasma concentrations of hepatocyte growth factor in acute leukemia in Upper Egypt. Egypt Pediatr Assoc Gaz. 2015;63(1):12-8. https://doi.org/10.4103/1110-1067.155789

Hjorth-Hansen H, Seidel C, Lamvik J, Börset M, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in acute myelocytic leukaemia. Eur J Haematol. 1999;62(2):129-34. https://doi.org/10.1111/j.1600-0609.1999. tb01733.x PMid:10052717

Aref S, Mabed M, Sakrana M, Goda T, El-Sherbiny M. Soluble hepatocyte growth factor (sHGF) and vascular endothelial growth factor (sVEGF) in adult acute myeloid leukemia: Relationship to disease characteristics. Hematology. 2002;7(5):273-9. https:// doi.org/10.1080/1024533021000037207 PMid:12850814

Kim JG, Sohn SK, Kim DH, Baek JH, Lee NY, Suh JS, et al. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia. Leuk Lymphoma. 2005;46(6):885-91. https://doi. org/10.1080/10428190500054491 PMid:16019534

Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001;15(8):1165-70. https://doi.org/10.1038/sj.leu.2402182 PMid:11480557

Sakon M, Kita Y, Takeda Y, Higaki N, Ohzato H, Umeshita K, et al. Measurement of hepatocyte growth factor in serum and plasma. Int J Clin Lab Res. 1999;29:110-3. https://doi. org/10.1007/s005990050073 PMid:10592107

How to Cite
Al-Bayaa IM, Al-Rubaie HA, Al-Shammari HH. Evaluation of Hepatocyte Growth Factor in Iraqi Patients with Acute Myeloid Leukemia: Its Correlation with Clinical Parameters and Response to Induction Therapy: its correlation with clinical parameters and response to induction therapy. Open Access Maced J Med Sci [Internet]. 2020Feb.25 [cited 2020Oct.31];8(B):49-3. Available from: https://www.id-press.eu/mjms/article/view/4235